Community - Public Portfolios & Trending Stocks | AllInvestView

Earnings Recaps

Browse reported earnings of the most popular stocks

Aug 14, 2026 Aug 13, 2026 Aug 12, 2026 Aug 11, 2026 Aug 10, 2026 Aug 9, 2026 Aug 8, 2026 Aug 7, 2026 Aug 6, 2026 Aug 5, 2026 Aug 4, 2026 Aug 3, 2026 Aug 2, 2026 Aug 1, 2026 Jul 31, 2026 Jul 30, 2026 Jul 29, 2026 Jul 28, 2026 Jul 27, 2026 Jul 26, 2026 Jul 25, 2026 Jul 24, 2026 Jul 23, 2026 Jul 22, 2026 Jul 21, 2026 Jul 20, 2026 Jul 19, 2026 Jul 18, 2026 Jul 17, 2026 Jul 16, 2026 Jul 12, 2026 Jul 11, 2026 Jul 10, 2026 Jul 9, 2026 Jul 3, 2026 Jul 2, 2026 Jul 1, 2026 Jun 30, 2026 Jun 28, 2026 Jun 27, 2026 Jun 26, 2026 Jun 25, 2026 Jun 24, 2026 Jun 20, 2026 Jun 19, 2026 Jun 18, 2026 Jun 17, 2026 Jun 15, 2026 Jun 14, 2026 Jun 13, 2026 Jun 12, 2026 Jun 11, 2026 Jun 10, 2026 Jun 9, 2026 Jun 6, 2026 Jun 5, 2026 Jun 4, 2026 Jun 3, 2026 Jun 2, 2026 Jun 1, 2026 May 31, 2026 May 30, 2026 May 29, 2026 May 28, 2026 May 27, 2026 May 26, 2026 May 24, 2026 May 23, 2026 May 22, 2026 May 21, 2026 May 20, 2026 May 19, 2026 May 18, 2026 May 17, 2026 May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025

28 companies Today

Aboitiz Power Corporation

ABZPF Q2 2026

Reported: 2026-08-11

AboitizPower delivered largely in line with expectations, with a flat market reaction reflecting balanced operational growth and offsetting pressures. While generation EBITDA and revenues showed solid increases, modest margin headwinds and one-off expenses in the distribution segment weighed on overall sentiment.

Key takeaways

Beneficial EBITDA grew 27% year-on-year to PHP 43.3 billion, driven primarily by a 30% increase in Generation EBITDA supported by higher contracted volumes, better market prices, and recent capacity additions.
Total beneficial revenue rose 28% to PHP 110 billion, benefiting from contributions from new solar assets and higher average bilateral and spot market prices.
Distribution segment’s energy sales increased 6%, but EBITDA declined 3% to PHP 4.3 billion due to one-off costs offsetting volume gains.
Renewable energy maintained a 27% market share with ongoing project developments and expansions in the green energy pipeline.
Net debt improved slightly to PHP 258.5 billion with a reduced net debt-to-equity ratio of 1.17x, reflecting conservative balance sheet management.

ACM Research, Inc.

ACMR Q2 2026

Reported: 2026-08-11

ACM Research reported revenue and shipments up 36% year-over-year with gross margin steady at 46%, yet the stock’s modest 0.5% gain suggests investors found the results largely in line with expectations without meaningful upside or notable concerns.

Key takeaways

Revenue reached $293 million, increasing 36% year-over-year, driven by strong growth in ECP and advanced packaging products (both up more than 150%).
Shipments also rose 36% to $282 million, with a shipment growth rate expected to continue outpacing revenue.
Gross margin held stable at 46%, and operating profit margin remained around 19%.
The order book saw a robust 105% increase year-over-year in the first half of 2026, backed by new panel-level plating technology orders from multiple customers.
Cash position remains strong with $1.4 billion gross cash and $1.0 billion net cash, following a recent $150 million registered direct offering.

Allianz SE

ALV.DE Q2 2026

Reported: 2026-08-11

Allianz’s stock declined modestly by 0.7% following its earnings release, reflecting cautious investor sentiment amid a mixed set of results with no clear catalyst to drive upside. While the company highlighted ongoing productivity gains and strong inflows in retirement assets, the market appears to have digested persistent geopolitical risks and only incremental progress in key segments.

Key takeaways

Expense ratio in P&C improved by 30 basis points, consistent with prior guidance, supporting underwriting discipline.
Mid-corporate combined ratio remained favorable at 88%, indicating controlled claims costs.
Retirement business reported record third-party net inflows of EUR 84 billion, reflecting strong client engagement and active management.
Acquisition of UOB Asset Management expands Southeast Asia presence, signaling commitment to growth in future markets.
Management acknowledged persistent macro uncertainties, including geopolitical tensions and inflationary pressures, without providing upside guidance adjustments.

Alpha Metallurgical Resources, Inc.

AMR Q2 2026

Reported: 2026-08-11

Alpha Metallurgical’s shares rose modestly by 1.1% following results that reflected ongoing headwinds including reduced shipment guidance and elevated costs, while operational disruptions at the DTA terminal continued to weigh on volumes and margins.

Key takeaways

Adjusted EBITDA decreased sequentially to $25.6 million in Q2 from $30 million in Q1, reflecting softer volumes and lower realizations.
Shipment volumes fell slightly to 3.5 million tons from 3.6 million tons in Q1, with FY 2026 shipment guidance lowered by 1 million tons amid terminal capacity limitations and weak global steel demand.
Cost of coal sales increased materially with the full-year guidance midpoint raised by $7 per ton due to higher diesel and materials costs driven by external factors such as the Iran war.
Operational challenges at DTA terminal, including storm damage to key equipment, continue to limit throughput and complicate recovery timelines.
Liquidity remains strong with $447.8 million available at quarter-end, though cash and short-term investments declined slightly from Q1; capex increased to $45.1 million, signaling ongoing investments amid uncertain volumes.

Amrize AG

AMRZ.SW Q2 2026

Reported: 2026-08-11

Amrize’s shares dropped 9.8% post-earnings as investors reacted to margin pressures driven by oil price-related cost inflation, despite solid revenue and earnings growth. The cautious tone on cost headwinds and less clarity on margin sustainability weighed on sentiment.

Key takeaways

Revenue grew 8.6% year-over-year, led by mega project demand from data centers, energy, and infrastructure modernization.
Organic growth reached 6.7%, signaling ongoing strength in core markets.
Net income and diluted EPS increased 14.4% and 14.7%, respectively, with adjusted EBITDA up 5.8%.
Cost inflation from higher freight, diesel, and raw materials notably pressured margins despite proactive pricing and fuel surcharges.
Significant capital investment ($241 million) and M&A activity (Rapid Redi-Mix acquisition) reflect a growth-focused capital allocation strategy.

Apple Hospitality REIT, Inc.

APLE Q2 2026

Reported: 2026-08-11

Shares fell 2.2% as investors appeared cautious despite modest upward revisions to RevPAR and margin guidance, reflecting concerns about more modest growth in the second half and a cautious outlook on acquisitions amid rising construction costs and pricing gaps.

Key takeaways

Comparable hotels RevPAR grew more than 5% in Q2, driven by broad-based demand improvements, with 75% of hotels showing growth.
Adjusted hotel EBITDA margin expanded by 120 basis points, converting 58¢ of each incremental revenue dollar into EBITDA.
Raised full-year RevPAR growth guidance by 25 basis points to 3.25% and comparable hotel EBITDA margin guidance by 75 basis points at the midpoint.
Management expects more modest growth in H2, despite describing their outlook as potentially conservative, and noted no agreements for acquisitions in 2026 amid valuation gaps and rising construction costs.
Completed refinancing that improved liquidity and capital structure, while continuing to selectively sell non-core assets and invest in renovations.

Banca Monte dei Paschi di Siena S.p.A.

BMPS.MI Q2 2026

Reported: 2026-08-11

MPS Group’s earnings report resulted in a muted market reaction, with shares edging up just 0.4%, reflecting a largely in-line performance without significant surprises on growth or profitability metrics.

Key takeaways

Second-quarter net profit exceeded EUR 600 million, contributing to a first-half total of more than EUR 1.1 billion.
Revenues increased 4.1% year-on-year for the first half, supported by solid fee growth (+3.6% y/y) and resilient net interest income (~EUR 2.1 billion H1).
Gross operating profit grew 8% in H1 to EUR 2.3 billion, with cost control leading to a 2 percentage point improvement in the cost-to-income ratio to 43%.
Customer loans expanded 5.6% year-on-year to EUR 151 billion, with funding remaining stable amid competitive conditions, supporting ongoing lending growth.
Commercial momentum remained steady, with customer financial assets reaching EUR 300 billion and wealth management inflows exceeding EUR 6 billion, highlighting solid franchise value but no material acceleration.

Celsius Holdings, Inc.

CELH Q2 2026

Reported: 2026-08-11

Celsius Holdings' stock fell 4.7% following a quarter that disappointed investors primarily due to cautious near-term growth signals and a lack of innovation-driven momentum, especially as the company delayed new product launches amid ongoing SKU rationalization and retail execution challenges.

Key takeaways

Q2 revenue reached $818 million, in line with the planned execution but lacking growth acceleration.
SKU optimization for CELSIUS brand led to reduced complexity but also slower momentum, with innovation deliberately delayed until early 2027.
Gross margins remained steady despite commodity cost pressures, reflecting margin resilience but no expansion.
Alani Nu showcased strong outperformance with 56% growth in tracked channels and surpassed $1 billion in retail sales, contributing positively to the portfolio.
Retail execution improvements are underway, including increased merchandising and closer retailer servicing, but retailer investment in cooler space delays contributed to uneven distribution gains.

TCG BDC, Inc.

CGBD Q2 2026

Reported: 2026-08-11

Shares rose 4.5% following a quarter that delivered solid origination growth and resilient income generation, driven by strong platform activity and expanding joint venture dividend yields.

Key takeaways

Closed $1.5 billion in new and incremental commitments at the platform level, with platform originations up over 20% from Q1.
Funded $248 million of investments at CGBD, supporting a net investment income of $0.35 per share, consistent with the dividend declared for Q3.
Joint ventures MMCF and SCP scaled portfolio investments to $1.2 billion and $1.7 billion respectively, with dividend yields rising to 17.6% and 18.7%.
Net asset value per share declined modestly from $15.89 to $15.61 amid a challenging macro backdrop.
Portfolio remains diversified across 177 companies in 25+ industries, with 95% senior secured loans and reduced leverage on new originations.

Collegium Pharmaceutical, Inc.

COLL Q2 2026

Reported: 2026-08-11

Collegium Pharmaceutical's shares dropped 17.5% following the earnings release, driven primarily by weakness in the NUCYNTA pain franchise due to pricing pressure from authorized generics and cautious outlook on sustaining pain portfolio revenue. Despite growth in the ADHD franchise, overall expectations for pain segment durability appear to have weighed heavily on investor sentiment.

Key takeaways

Jornay PM prescriptions grew 13.1% year-over-year, generating $46.1 million in net revenue, up 41% year-over-year, with prescribers reaching a record 30,000, up 17.6%.
The acquisition of Azstarys in May has expanded the ADHD portfolio, with revenue expectations raised to $65-$75 million for the partial year.
Pain portfolio revenue totaled $140.9 million, with Belbuca up 10% year-over-year but offset by NUCYNTA revenue declines due to authorized generic pricing impacts.
Formulary access was expanded by 9 million lives for Belbuca, effective in Q4, but concerns remain about the pain franchise's sustainability.
Company reiterated confidence in full-year ADHD revenue targets but signaled ongoing challenges in maximizing and maintaining pain portfolio returns amid pricing pressures.

Douglas Elliman Inc.

DOUG Q2 2026

Reported: 2026-08-11

Douglas Elliman’s shares rose modestly by 2.2% post-earnings, reflecting cautious investor reception amid early-stage AI investments and broadened service offerings without evident near-term margin expansion or guidance shifts.

Key takeaways

The company launched a dual-track AI transformation: modernization of tech infrastructure with Google Cloud and creation of Elius, an intelligence unit leveraging proprietary data for new revenue streams.
Expanding its international footprint, Douglas Elliman opened an office in Paris and pursued growth in France, Monaco, and St. Barts, signaling a strategic push into luxury markets.
The Elliman Capital lending platform broadened presence into California and Texas, enhancing integrated mortgage solutions and diversifying revenue beyond commissions.
Recent months showed improving cash receipts from existing home sales, with a 15-16% increase in May and June 2026 compared to last year, continuing into July at +8%.
Despite positive business developments and stable financial positioning—with no long-term debt and over $100 million cash on hand—investors appear to be awaiting clearer evidence of margin improvement or financial impact from new initiatives.

EPAM Systems, Inc.

EPAM Q2 2026

Reported: 2026-08-11

EPAM’s shares dropped 11.3% as investors reacted negatively to noticeable deceleration and weakness in the North American business, as well as pressure from margin headwinds and cautious outlook commentary.

Key takeaways

Revenue grew 4.5% year-over-year on a reported basis, with organic constant currency growth of 3.4%, but growth was uneven across verticals and regions.
Four of six verticals recorded growth, led by Financial Services and Life Sciences & Healthcare; however, Software & Hi-Tech and Business Information & Media declined, with the latter impacted by project completions.
Americas region showed significantly lower growth compared to strong double-digit expansion in EMEA.
Management highlighted ongoing “growth gaps” in key parts of the North American business, signaling execution challenges despite strategic investments.
EPAM is investing heavily in AI-related capabilities and commercial transformation, but these forward-looking efforts have yet to offset near-term deceleration and cautious client budget sentiments amid geopolitical uncertainty.

Eregli Demir ve Celik Fabrikalari T.A.S.

EREGL.IS Q2 2026

Reported: 2026-08-11

Shares declined 6.9% following Erdemir’s earnings as investors reacted negatively to margin compression amid weak global demand and cautious outlook driven by geopolitical and regulatory headwinds.

Key takeaways

First half 2026 revenue reached $2.8 billion with EBITDA at $281 million and net profit of $201 million, supported by a one-off deferred tax income related to a 2027 corporate tax cut.
Crude steel capacity utilization improved to 95%, with sales volume at 4.2 million tonnes in H1, targeting over 8.2 million tonnes for full-year 2026.
Export volumes accounted for 14% of sales, with the domestic market remaining the primary revenue driver despite import pressures.
Global steel pricing was pressured by weak demand, geopolitical tensions, and volatile energy costs, limiting pricing recovery and exerting margin pressure.
The new EU steel import regime and CBAM increased pricing and quota risks for exports, limiting growth visibility in key markets.

Evolent Health, Inc.

EVH Q2 2026

Reported: 2026-08-11

Evolent’s shares surged 28.2% following an earnings report that beat expectations on revenue growth, early positive performance from new contracts, and accelerating AI-driven efficiency gains.

Key takeaways

Q2 revenue rose 31% sequentially to $653 million, driven by new and expanded customer partnerships.
Adjusted EBITDA grew 27% quarter-over-quarter to $28 million, supported by higher volumes and operational improvements.
Medical Expense Ratio (MER) increased to 95% from 93% due to the May 2026 launch of the Highmark contract.
Strong contract renewal momentum, including key agreements with Aetna, Highmark, and a regional Blue Cross plan, providing visibility into 2027.
AI-powered authorization approvals reached 75%, up from 55%, streamlining claims processing and reducing administrative burdens, signaling meaningful cost and productivity improvements.

Extendicare Inc.

EXE.TO Q2 2026

Reported: 2026-08-11

Shares dropped 4.9% following earnings as investors reacted negatively to margin compression in the home health care segment amid rapid volume growth and no rate increases in Ontario.

Key takeaways

Consolidated Q2 revenue rose 59.4% to $611 million, driven by acquisitions including CBI and Closing the Gap, and organic growth in home health care.
Adjusted EBITDA increased 71.7% year over year to $68.3 million, reflecting acquisition activity and organic expansion.
Home health care volumes grew 133% year over year, with same-store ADV up 31.7%, but NOI margins declined 60 basis points due to increased investments and lack of 2026 Ontario rate increases.
Long term care segment showed solid occupancy and funding enhancements supporting NOI growth of $5.7 million and trailing 12-month margins of 11.8%.
AFFO per share rose 52.9% to $0.448, though this was partly offset by elevated stock compensation costs related to board retirements.

Fidus Investment Corporation

FDUS Q2 2026

Reported: 2026-08-11

Fidus shares declined 3.6% post-earnings, reflecting investor disappointment with a noticeable deceleration in fee income and margin pressure from higher interest expenses, despite stable recurring income and portfolio health.

Key takeaways

Adjusted net investment income (NII) covered the base dividend at $0.50 per share, supported by $6.4 million ($0.17 per share) in net realized gains from equity monetizations.
Total investment income fell $4 million sequentially to $43.5 million, mainly due to a $6.8 million decline in fee income related to the absence of one-time fees recognized in Q1.
Total expenses increased $1.9 million versus Q1, driven by a $1.2 million rise in interest expense tied to higher debt balances and refinancing costs, compressing margins.
Originations remained robust at $98 million, with a focus on M&A-driven first lien investments, supporting portfolio diversification valued at $1.4 billion.
Credit quality remains solid with only one nonaccrual at quarter-end, which was subsequently resolved with a realized loss, leaving no current nonaccruals.

Hawaiian Electric Industries, Inc.

HE Q2 2026

Reported: 2026-08-11

HEI's shares fell 6.5% after the quarter on concerns around cautious outlook and ongoing regulatory and rate reset uncertainties, which overshadowed operational updates and incremental project approvals.

Key takeaways

The company remains in a transitional year ahead of a planned rate reset in 2027, with a $170 million proposed base rate increase phased over two years, but final regulatory approval is pending.
Recent PUC responses imposed additional requirements for demonstrating need on proposed new generation procurement, adding regulatory scrutiny.
Wildfire Mitigation Plan (WMP) cost recovery will likely shift from the Exceptional Project Recovery Mechanism to securitization, with ongoing work to secure regulatory approval.
Several renewable energy projects, including solar plus storage PPAs from the 2023 Stage 3 RFP, received approvals, supporting the company’s renewable capacity expansion targets.
Significant capital investments totaling over $1.3 billion through 2035 are planned for grid modernization, resilience, and interconnection points.

Hamilton Insurance Group, Ltd.

HG Q2 2026

Reported: 2026-08-11

Hamilton's shares declined 2.0% in reaction to Q2 results that reflected ongoing margin pressure and cautious commentary on a competitive market, particularly in the property segment. The modest stock pullback suggests investors are wary of the limited pricing power and the company’s selective underwriting stance amid heightened geopolitical and inflationary headwinds.

Key takeaways

Net income of $144 million translated to an annualized return on average equity of 21%, supported by a combined ratio of 95% that includes $50 million of catastrophe losses related to Middle East conflict.
Gross premiums written increased 17% overall, with the international segment up 22% and Bermuda segment up 12%, driven primarily by specialty and casualty classes.
Midyear renewals reflect competitive pressures especially in property; pricing remains attractive in many lines, but management is increasingly selective, declining business that does not meet return thresholds.
The Hamilton Select platform grew 18%, expanding its risk appetite beyond hard-to-place risks to include lower middle market segments and new classes, backed by a recent AM Best rating upgrade to A.
Management emphasized margin preservation, risk selection discipline, and prudent use of outward protection such as the newly launched casualty sidecar to navigate a challenging environment.

Leon's Furniture Limited

LNF.TO Q2 2026

Reported: 2026-08-11

LFL Group’s shares declined 2% following Q2 results as deceleration in core categories and ongoing margin pressure tempered investor enthusiasm amid a cautious consumer environment.

Key takeaways

Revenue declined 2% year-over-year to $631.2 million, reflecting a cautious and value-conscious consumer.
Same-store sales decreased 2.2%, driven by customers trading down to lower price points, particularly impacting average ticket size.
Furniture sales dropped 4.2% versus a strong 6% growth in the prior year quarter; unit sales were slightly down.
Mattress category continued growth for the second consecutive quarter, mitigating some weakness elsewhere.
Commercial channel sales edged down amid a challenging builder market, though gains in property management and Western expansion helped offset softness in Ontario.

Loma Negra Compania Industrial Argentina Sociedad Anonima

LOMA Q2 2026

Reported: 2026-08-11

Shares declined 4.3% as investors reacted negatively to volume deceleration and margin compression driven by weak April demand and rising costs, overshadowing modest revenue growth and operational resilience.

Key takeaways

Cement volumes dropped 1.4% year-over-year, primarily due to heavy rains in April; May and June volumes normalized but remained flat versus last year.
Consolidated net revenue grew 2.1% to Ps. 238.1 billion, supported by pricing improvements despite volume headwinds.
Adjusted EBITDA fell 2.5% year-over-year to Ps. 48.2 billion, with margins contracting by 97 basis points to 20.2%, pressured by higher costs and depreciation.
Gross margin declined 122 basis points to 19.2%, reflecting increased costs in cement and railroad segments, including packaging, freight, and depreciation linked to the new bagging project.
Concrete and Aggregate segments saw double-digit volume declines (18.6% and 12.2%, respectively), weighed down by delayed infrastructure projects, partially offset by pricing gains.

MDA Space Ltd

MDA Q2 2026

Reported: 2026-08-11

Shares declined 2.5% following Q2 results, reflecting investor caution despite solid revenue growth, likely due to a cautious outlook and lack of margin improvement commentary that tempered enthusiasm.

Key takeaways

Revenue rose 34% year-over-year in Q2, with adjusted EBITDA margin stable at 19.3%.
Year-to-date revenue reached $963 million, up 33%; adjusted EBITDA margin held at 19.4%.
Management raised full-year revenue and EBITDA midpoint guidance to $1.85 billion and $350 million respectively, implying continued double-digit organic growth.
Strong book-to-bill ratio of 1.6x driven by government and defense contracts across multiple geographies.
Significant new contract awards include $474 million added to Telesat Lightspeed constellation and a $600 million follow-on Canadian Space Agency satellite contract.

Monmouth Real Estate Investment Corporation

MNR Q2 2026

Reported: 2026-08-11

Shares of Mach Natural Resources declined 1.1% following the Q2 2026 earnings update as investors responded to cautious commentary on capital deployment and leverage, despite the company maintaining its disciplined acquisition strategy and distribution policy.

Key takeaways

The company reiterated its four strategic pillars focused on disciplined acquisitions, reinvestment under 50% of operating cash flow, managing leverage, and maximizing distributions.
Leverage is currently projected at 1.4x debt to EBITDA by year-end, above the company’s stated target of 1.0x, with a multi-year plan to reduce this by 2027.
Acquisition activity remains focused on discounted, cash-flowing assets, though management acknowledged increased competition and premium prices in key regions like the MidCon.
The distribution yield has consistently been high, around 15% since 2024, supported by a strong cash return on capital invested averaging 35% over five years.
Drilling activity was deliberately paced to stay within CapEx limits, with a current emphasis on oil drilling over natural gas to maintain rates of return given the capital constraints.

Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft in Munchen

MUV2.DE Q2 2026

Reported: 2026-08-11

Munich Re's shares declined 1.4% post-earnings, reflecting investor caution despite the company’s steady execution amid ongoing challenges in P&C reinsurance pricing and volume declines. The market appears to weigh persistent pressure on P&C rates and cautious volume management more heavily than diversification gains.

Key takeaways

Net income reached EUR 3.9 billion in H1, over 60% of full-year guidance, supported by low major losses and equity market strength.
Return on equity stood at 23%, above the medium-term target of 18%.
P&C reinsurance revenue declined due to a 9% volume contraction and a 5.5% price decrease in July renewals, with no sign of pricing stabilization or improvement.
Growth in Global Specialty Insurance (GSI), Life Re, and ERGO partially offset P&C softness, supporting earnings diversification efforts.
Management maintained underwriting discipline by exiting low-profit business, especially in XL segments, indicating ongoing risk aversion amid a challenging pricing environment.

OSISKO GOLD ROYALTIES LTD

OR Q2 2026

Reported: 2026-08-11

OR Royalties' stock inched up 2.6% following its Q2 report, reflecting a performance largely in line with expectations despite near-term headwinds from Canadian Malartic's pit wall incident, which reduced upcoming gold equivalent ounces. The market appears cautiously receptive to the company's maintained guidance and continued portfolio ramp-ups.

Key takeaways

Q2 revenues rose 62% year-over-year to $97.8 million, supported by a 5% increase in gold equivalent ounces (GEOs) and strong realized precious metals prices.
Operating cash flow reached $83.2 million, reflecting a sector-leading cash margin of approximately 97% of revenue.
Canadian Malartic experienced a significant rock mass movement, resulting in an estimated 18,500 fewer GEOs to OR Royalties over 2026-2028; however, full-year 2026 guidance (80,000–90,000 GEOs) remains intact.
Other assets had mixed performances: Dalgaranga delivered first royalties this quarter; Namdini's ramp-up contributed significantly; CSA faced logistical delays causing inventory buildup; Mantos Blancos saw a decline due to earlier front-loaded silver grades.
The company closed two acquisitions totaling $335 million, funded largely by its revolver with $215 million drawn at quarter-end, positioning for accretive growth opportunities in H2 2026 and beyond.

Runway Growth Finance Corp.

RWAY Q2 2026

Reported: 2026-08-11

Shares rallied 10.9% following the earnings release, driven by investor enthusiasm around the strategic leadership additions, enhanced portfolio diversification via the SWK transaction, and strong alignment indicated by BC Partners’ sizable stock purchase commitment.

Key takeaways

Newly appointed Co-CEO Mike Rovner brings extensive experience in venture lending and private credit, strengthening the firm's leadership and investment capabilities.
The SWK transaction significantly diversified the portfolio by industry and loan size, enhancing risk management and growth potential.
BC Partners committed to buying up to 10% of outstanding shares over two years at discounts below 70% of NAV, signaling confidence and providing potential stock demand support.
The company maintained a disciplined approach to underwriting, active portfolio management, and capital allocation despite a challenging environment characterized by tighter credit scrutiny and cautious sentiment in the software sector.
Shares trade at a steep discount to NAV (~49% as of August 4), but management views this as an overestimation of portfolio stress and undervaluation of underlying fundamentals.

Rayonier Inc.

RYN Q2 2026

Reported: 2026-08-11

Rayonier's shares declined 1.0% following Q2 results as improving lumber prices and volume gains were offset by ongoing softness in pulpwood markets and modest margin pressures, leaving investors somewhat cautious despite progress on integration and portfolio optimization.

Key takeaways

GAAP earnings came in at $0.06 per share, with adjusted net income of $0.10 per share after pro forma merger-related adjustments.
Adjusted EBITDA rose to $124 million, supported by contributions from PotlatchDeltic and operational performance across segments.
Southern Timber segment saw harvest volumes double year-over-year, though pricing weakened in pulpwood markets amid subdued demand and salvage harvesting from regional fires.
Northwest Timber EBITDA increased sharply, driven by doubled harvest volumes and improved sawlog prices linked to rising lumber prices.
Wood Products segment reported its strongest adjusted EBITDA since 2022 Q3, with lumber prices up 18% sequentially, aided by supply constraints; however, increased transportation costs pressured margins, largely passed through to customers.

Twilio Inc.

TWLO Q2 2026

Reported: 2026-08-11

Shares of Twilio surged 24.9% following Q2 2026 results, driven by stronger-than-expected revenue growth and accelerating non-GAAP gross profit expansion, alongside robust client adoption of new AI-powered conversational products.

Key takeaways

Reported $1.5 billion in revenue with 17% year-over-year organic growth, indicating accelerating top-line momentum.
Non-GAAP gross profit grew 18% year-over-year, outpacing revenue growth and supporting operational leverage.
Generated $285 million in non-GAAP income from operations and $353 million in free cash flow, underscoring solid cash generation.
Successfully launched the next-generation conversations layer platform and redesigned Twilio Console, driving multiproduct adoption and increased customer engagement.
Secured multiple large-scale deals, including 7- and 8-figure contracts with clients across industries, validating demand for Twilio’s AI-enhanced communication infrastructure.

United Therapeutics Corporation

UTHR Q2 2026

Reported: 2026-08-11

United Therapeutics’ shares declined 0.6% following Q2 results that showed flat revenue and a cautious tone from management, suggesting investors were underwhelmed by the lack of near-term growth acceleration despite promising clinical progress.

Key takeaways

Total Q2 revenue came in at approximately $783 million, essentially flat with Q1, indicating a pause in growth momentum.
Management highlighted recent clinical successes and multiple late-stage filings but provided limited near-term commercial upside.
The company reiterated expectations for potential approvals in 2027 for key pipeline assets, underscoring a longer timeline to material new revenue streams.
Investment in xenotransplantation programs and the acquisition of Thymmune Therapeutics broaden the pipeline but increase capital allocation away from core commercial growth.
Operating efficiency remains a focus, but the flat quarter and cautious outlook contributed to muted investor response.

Community

See what investors are trading, holding, and sharing

🌐

📈

📊

🏦

🪙

💱

#	Asset	Price	Community %	Type	Currency	Sector

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Changelog Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.